Literature DB >> 21865347

An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations.

Maria Romano1, Maria Donata Di Taranto, Peppino Mirabelli, Maria Nicoletta D'Agostino, Arcangelo Iannuzzi, Gennaro Marotta, Marco Gentile, Maddalena Raia, Rosa Di Noto, Luigi Del Vecchio, Paolo Rubba, Giuliana Fortunato.   

Abstract

The main causes of familial hypercholesterolemia (FH) are mutations in LDL receptor (LDLR) gene. Functional studies are necessary to demonstrate the LDLR function impairment caused by mutations and would be useful as a diagnostic tool if they allow discrimination between FH patients and controls. In order to identify the best method to detect LDLR activity, we compared continuous Epstein-Barr virus (EBV)-transformed B-lymphocytes and mitogen stimulated T-lymphocytes. In addition, we characterized both novel and known mutations in the LDLR gene. T-lymphocytes and EBV-transformed B-lymphocytes were obtained from peripheral blood of 24 FH patients and 24 control subjects. Functional assays were performed by incubation with fluorescent LDL followed by flow cytometry analysis. Residual LDLR activity was calculated normalizing fluorescence for the mean fluorescence of controls. With stimulated T-lymphocytes we obtained a better discrimination capacity between controls and FH patients compared with EBV-transformed B-lymphocytes as demonstrated by receiver operating characteristic (ROC) curve analysis (the areas under the curve are 1.000 and 0.984 respectively; P < 0.0001 both). The characterization of LDLR activity through T-lymphocytes is more simple and faster than the use of EBV-transformed B-lymphocytes and allows a complete discrimination between controls and FH patients. Therefore the evaluation of residual LDLR activity could be helpful not only for mutation characterization but also for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865347      PMCID: PMC3196240          DOI: 10.1194/jlr.D017772

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  25 in total

1.  Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent.

Authors:  J Wang; E Huff; L Janecka; R A Hegele
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

2.  LDL receptor cDNA sequence analysis in familial hypercholesterolemia patients: 5 novel mutations with high prevalence in families originating from southern Italy.

Authors:  R Liguori; A M Bianco; A Argiriou; P Pauciullo; A Giannino; P Rubba; V De Simone
Journal:  Hum Mutat       Date:  2001-05       Impact factor: 4.878

3.  Surface expression of low density lipoprotein receptor in EBV-transformed lymphocytes: characterization and use for studying familial hypercholesterolemia.

Authors:  P Chan; C Jones; R Lafrenière; H G Parsons
Journal:  Atherosclerosis       Date:  1997-06       Impact factor: 5.162

4.  Flow cytometric assessment of LDL receptor activity in peripheral blood mononuclear cells compared to gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia.

Authors:  B Raungaard; F Heath; J U Brorholt-Petersen; H K Jensen; O Faergeman
Journal:  Cytometry       Date:  1999-05-01

5.  Flow cytometric measurement of low density lipoprotein receptor activity validated by DNA analysis in diagnosing heterozygous familial hypercholesterolemia.

Authors:  P Urdal; T P Leren; S Tonstad; P K Lund; L Ose
Journal:  Cytometry       Date:  1997-10-15

6.  Improved detection of familial hypercholesterolemia by determining low density lipoprotein receptor expression in mitogen-induced proliferating lymphocytes.

Authors:  P C Chan; A Edwards; R Lafrenière; H G Parsons
Journal:  J Lipid Res       Date:  1998-11       Impact factor: 5.922

7.  Non-sterol regulation of low density lipoprotein receptor gene expression in T cells.

Authors:  R S Makar; P E Lipsky; J A Cuthbert
Journal:  J Lipid Res       Date:  1994-10       Impact factor: 5.922

8.  Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells.

Authors:  K Løhne; P Urdal; T P Leren; S Tonstad; L Ose
Journal:  Cytometry       Date:  1995-08-01

9.  FH-Sydney 1 and 2: two novel frameshift mutations in exon 10 of the low-density lipoprotein receptor gene detected by heteroduplex formation.

Authors:  J A Cavanaugh; S Easteal; L A Simons; D W Thomas; S W Serjeantson
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

10.  Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project.

Authors:  A Taylor; D Wang; K Patel; R Whittall; G Wood; M Farrer; R D G Neely; S Fairgrieve; D Nair; M Barbir; J L Jones; S Egan; R Everdale; Y Lolin; E Hughes; J A Cooper; S G Hadfield; G Norbury; S E Humphries
Journal:  Clin Genet       Date:  2010-03-13       Impact factor: 4.438

View more
  8 in total

1.  Characterization of two novel pathogenic variants at compound heterozygous status in lipase maturation factor 1 gene causing severe hypertriglyceridemia.

Authors:  Miklós Péterfy; Candy Bedoya; Carola Giacobbe; Carmen Pagano; Marco Gentile; Paolo Rubba; Giuliana Fortunato; Maria Donata Di Taranto
Journal:  J Clin Lipidol       Date:  2018-07-25       Impact factor: 4.766

2.  Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports.

Authors:  Maria Donata Di Taranto; Monica Gelzo; Carola Giacobbe; Marco Gentile; Gennaro Marotta; Silvia Savastano; Antonio Dello Russo; Giuliana Fortunato; Gaetano Corso
Journal:  Metab Brain Dis       Date:  2016-05-26       Impact factor: 3.584

3.  Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment.

Authors:  Aitor Etxebarria; Asier Benito-Vicente; Ana C Alves; Helena Ostolaza; Mafalda Bourbon; Cesar Martin
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

4.  Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.

Authors:  Maria Donata Di Taranto; Asier Benito-Vicente; Carola Giacobbe; Kepa Belloso Uribe; Paolo Rubba; Aitor Etxebarria; Ornella Guardamagna; Marco Gentile; Cesar Martín; Giuliana Fortunato
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

Review 5.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

6.  Multiparametric platform for profiling lipid trafficking in human leukocytes.

Authors:  Simon G Pfisterer; Ivonne Brock; Kristiina Kanerva; Iryna Hlushchenko; Lassi Paavolainen; Pietari Ripatti; Mohammad Majharul Islam; Aija Kyttälä; Maria D Di Taranto; Annalisa Scotto di Frega; Giuliana Fortunato; Johanna Kuusisto; Peter Horvath; Samuli Ripatti; Markku Laakso; Elina Ikonen
Journal:  Cell Rep Methods       Date:  2022-02-08

7.  Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.

Authors:  Maria Donata Di Taranto; Carola Giacobbe; Daniela Palma; Gabriella Iannuzzo; Marco Gentile; Ilenia Calcaterra; Ornella Guardamagna; Renata Auricchio; Matteo Nicola Dario Di Minno; Giuliana Fortunato
Journal:  Clin Genet       Date:  2021-08-03       Impact factor: 4.296

8.  A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia.

Authors:  Maria Donata Di Taranto; Carola Giacobbe; Alessio Buonaiuto; Ilenia Calcaterra; Daniela Palma; Giovanna Maione; Gabriella Iannuzzo; Matteo Nicola Dario Di Minno; Paolo Rubba; Giuliana Fortunato
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.